WHAT YOU NEED TO KNOW CAPA Points To Patent Quality As Key To Ultimately Lowering Prescription Drug Prices In a recent op-ed as part of Patent Quality Week, CAPA Executive Director Matthew Lane outlined the ways in which the pharmaceutical marketplace is impacted by Big Pharma’s manipulation and abuse of the U.S. patent system. Particularly, Lane dives […]

Continue Reading

IN CASE YOU MISSED IT: This week, Techdirt published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), as a part of their series around Patent Quality Week. In his op-ed, Lane outlines the ways in which the pharmaceutical marketplace is impacted by Big Pharma’s manipulation and abuse of the U.S. patent system.  Specifically, […]

Continue Reading

Join the Discussion to Learn More About How the U.S Public is a Vital Stakeholder in the U.S. Patent System. WASHINGTON D.C. – As part of Patent Quality Week, the Public Interest Patent Law Institute and the Coalition Against Patent Abuse (CAPA) are hosting a conversation highlighting how patent law does – or at least should – […]

Continue Reading

WHAT YOU NEED TO KNOW TUESDAY, JULY 20: The Coalition Against Patent Abuse (CAPA) is hosting a panel with the Public Interest Patent Law Institute highlighting how patent law can impact every American, particularly when it comes to high drug prices. The event will feature a discussion moderated by CAPA Executive Director Matthew Lane and include the […]

Continue Reading

Join the Discussion to Learn More About How the U.S Public is a Vital Stakeholder in the U.S. Patent System. WASHINGTON D.C. – As part of Patent Quality Week, the Public Interest Patent Law Institute and the Coalition Against Patent Abuse (CAPA) are hosting a conversation highlighting how patent law does – or at least should – […]

Continue Reading

Part VI: IPR & Anemia – An Effective, Low-Cost Tool for Resolving Patent Disputes Since the inter partes review (IPR) process was established under the America Invents Act in 2011, IPR has become a popular and cost-effective tool compared to traditional patent litigation.  Even the U.S. Supreme Court has described the IPR process as a way to […]

Continue Reading

Lawmakers Must Continue to Work with Industry Leaders, Experts to Prevent Manipulations of the U.S. Patent System WASHINGTON D.C. – Today, the Senate Judiciary Subcommittee on Competition Policy, Antitrust, and Consumer Rights held a hearing entitled, “A Prescription for Change: Cracking Down on Anticompetitive Conduct in Prescription Drug Markets” to examine anticompetitive tactics used by many […]

Continue Reading

WHAT YOU NEED TO KNOW The Coalition Against Patent Abuse’s Executive Director Matthew Lane penned an op-ed in Morning Consult recently on the need to address patent abuse and anti-competitive pricing tactics used by some major pharmaceutical companies. In his op-ed, Mr. Lane dives into the current imbalance between rewarding new drug innovations and competition from low-cost alternatives.  […]

Continue Reading